New Alzheimer’s Drug Lecanemab Approved in Australia: What You Need too Know
Australia has taken a significant step forward in the fight against Alzheimer’s disease with the recent approval of Lecanemab by the Therapeutic Goods Administration (TGA). This marks a new potential treatment option, but access and affordability remain key considerations. Here’s a comprehensive look at what this means for you and your loved ones.
A Promising, Though Early, Treatment
Lecanemab is designed for individuals in the very early stages of Alzheimer’s disease. It works by targeting and clearing amyloid plaques, a hallmark of the disease, from the brain. Professor Christopher Rowe, a leading expert in the field, emphasizes that this isn’t a cure, but a potential way to slow disease progression.
Importantly, the TGA approved Lecanemab with a specific restriction: it’s only for those without the APOE4 gene. This genetic marker is associated with increased risk and potentially different responses to the treatment.
Understanding the Risks & Benefits
While promising,Lecanemab isn’t without potential side effects. Professor Rowe reports a less than 1% chance of developing a serious adverse reaction. Though, regular monitoring, including frequent MRI scans, is crucial.
Clinical trials have demonstrated a consistent benefit of approximately six months in slowing cognitive decline. This is a key difference from another recently approved drug, Donanemab, which was deemed by the Pharmaceutical Benefits Scheme (PBS) to offer too small a benefit to justify its cost.
Who is Eligible for Lecanemab?
The drug is administered via fortnightly intravenous infusions. Here’s a breakdown of who might qualify:
* Early Stage Diagnosis: You must be diagnosed with mild cognitive impairment or early-stage Alzheimer’s disease.
* APOE4 Gene Status: You must not carry the APOE4 gene.Genetic testing will be required.
* Access to Specialists: You’ll need access to specialists capable of administering the infusions and interpreting MRI scans.
The Cost Factor: A Significant Barrier
Currently, the biggest hurdle to accessing Lecanemab is its cost. A year’s treatment runs approximately $39,974,and the total cost,including infusions and monitoring,can quickly escalate to $100,000.
This price point puts the drug out of reach for most Australians. Widespread access hinges on its inclusion on the Pharmaceutical Benefits Scheme (PBS). If listed on the PBS, the cost would be considerably subsidized, making it affordable for many more patients.
why Early Diagnosis is More Significant Than Ever
lecanemab’s effectiveness is limited to the early stages of the disease. This underscores the critical importance of early diagnosis.
If you or a loved one is experiencing noticeable memory decline, don’t delay. See your doctor for a comprehensive assessment. Early intervention is key to maximizing potential treatment options.
what Happened with Donanemab?
Earlier this year, the TGA also approved donanemab, another amyloid-clearing drug. Though, the PBS rejected its listing due to concerns about its limited clinical benefit – trials suggested only a six-week improvement.
Professor Rowe is optimistic that lecanemab’s more ample six-month benefit will sway the PBS towards approval. He notes the significant “desperate” need among patients for effective treatments.
Looking Ahead
The approval of Lecanemab represents a beacon of hope for those affected by Alzheimer’s disease. Though, navigating the eligibility criteria, cost, and access challenges will require ongoing advocacy and collaboration between healthcare professionals, policymakers, and patient support groups.
Resources:
* ABC News Report on Lecanemab and Donanemab
* Alzheimer’s Disease International
Disclaimer: *I am an AI chatbot and cannot
Worth a look